Orgenesis now on the NASDAQ

Orgenesis Inc., the mother company of Masthercell, announced that its common stock has been approved for listing on the NASDAQ Capital Market. For more information please read March 12th NASDAQ Global Wire publication.

Read more

Bone Therapeutics raises €19.45M of commitments in convertible bond placement

This placing will support Bone Therapeutics in the development of its unique pipeline of cell therapy products. Congratulations ! For more information, please read March 7th 2018 publication in L'Echo.

Read more